{"DataElement":{"publicId":"6028582","version":"2","preferredName":"Manufacture Cellular Therapy Product Type","preferredDefinition":"A description of the manufactured cellular therapy product.","longName":"6028557v1.0:6028570v1.1","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"6028557","version":"1","preferredName":"Manufacture Cellular Therapy Product","preferredDefinition":"The act of making something (a product) from raw materials._Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy._A thing produced by or resulting from a process. EXAMPLE(S): drug, device. The FDA list of regulated products: animal and human drugs; therapeutic biologics; allergenics; cell, tissue and gene therapy products; blood components; blood derivative products; devices; and animal (pets and livestock) and human food/feed (medicated and un-medicated); cosmetics; pet treats; and dietary supplements.","longName":"6028555v1.0:2955730v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"6028555","version":"1","preferredName":"Manufacture Cellular Therapy","preferredDefinition":"The act of making something (a product) from raw materials.:Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.","longName":"C43360:C70601","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Manufacture","conceptCode":"C43360","definition":"The act of making something (a product) from raw materials.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cellular Therapy","conceptCode":"C70601","definition":"Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E1B9DEE-9DB3-2601-E053-F662850A15FF","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2955730","version":"1","preferredName":"Product","preferredDefinition":"The end result of a manufacturing process; anything that is produced.","longName":"C51980","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Product","conceptCode":"C51980","definition":"The end result of a manufacturing process; anything that is produced.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"76966310-6AD4-73E7-E040-BB89AD4379EA","latestVersionIndicator":"Yes","beginDate":"2009-10-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-10-23","modifiedBy":"ONEDATA","dateModified":"2009-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435032","version":"1","preferredName":"Property or Attribute","preferredDefinition":"The distinguishing qualities or prominent aspect of a person, object, action, process, or substance.","longName":"C20189","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-8321-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E1B9DEE-9DC1-2601-E053-F662850A15FF","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-16","modifiedBy":"NYCHM","dateModified":"2018-02-12","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6028570","version":"1.1","preferredName":"Manufacture Cellular Therapy Product Type","preferredDefinition":"The act of making something (a product) from raw materials._Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy._A thing produced by or resulting from a process. EXAMPLE(S): drug, device. The FDA list of regulated products: animal and human drugs; therapeutic biologics; allergenics; cell, tissue and gene therapy products; blood components; blood derivative products; devices; and animal (pets and livestock) and human food/feed (medicated and un-medicated); cosmetics; pet treats; and dietary supplements._Something distinguishable as an identifiable class based on common qualities.","longName":"6028570v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other product","valueDescription":"Other Product","ValueMeaning":{"publicId":"6028571","version":"1","preferredName":"Other Product","longName":"6028571","preferredDefinition":"Different than the one(s) previously specified or mentioned.: The end result of a manufacturing process; anything that is produced.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Product","conceptCode":"C51980","definition":"The end result of a manufacturing process; anything that is produced.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E1BE14D-4030-4549-E053-F662850A290A","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B294EAA6-913B-4A7B-E053-4EBD850A48B0","beginDate":"2017-11-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-26","modifiedBy":"ONEDATA","dateModified":"2020-10-26","deletedIndicator":"No"},{"value":"Tisagenlecleucel","valueDescription":"CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes","ValueMeaning":{"publicId":"5621736","version":"1","preferredName":"CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes","longName":"5621736","preferredDefinition":"Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD19CAR-CD3zeta-4-1BB-expressing autologous T-lymphocytes direct the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tisagenlecleucel","conceptCode":"C102758","definition":"Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, tisagenlecleucel directs the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BD2A-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B294EAA6-9145-4A7B-E053-4EBD850A48B0","beginDate":"2017-11-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-26","modifiedBy":"ONEDATA","dateModified":"2020-10-26","deletedIndicator":"No"},{"value":"Lisocabtagene maraleucel","valueDescription":"Lisocabtagene Maraleucel","ValueMeaning":{"publicId":"6845581","version":"1","preferredName":"Lisocabtagene Maraleucel","longName":"6845581","preferredDefinition":"A preparation of a defined ratio of CD4+ and CD8+ autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, lisocabtagene maraleucel are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lisocabtagene Maraleucel","conceptCode":"C125192","definition":"A preparation of a defined ratio of CD4+ and CD8+ autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, lisocabtagene maraleucel is directed to and induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F2829E4-235D-2993-E053-F662850AB7EA","latestVersionIndicator":"Yes","beginDate":"2019-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-08-02","modifiedBy":"ONEDATA","dateModified":"2019-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B294EAA6-914F-4A7B-E053-4EBD850A48B0","beginDate":"2019-08-02","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-26","modifiedBy":"ONEDATA","dateModified":"2020-10-26","deletedIndicator":"No"},{"value":"Axicabtagene ciloleucel","valueDescription":"Axicabtagene Ciloleucel","ValueMeaning":{"publicId":"6028573","version":"1","preferredName":"Axicabtagene Ciloleucel","longName":"6028573","preferredDefinition":"A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a gammaretoviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of axicabtagene ciloleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it regulates both the assembly and cell surface expression of TCR complexes. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Axicabtagene Ciloleucel","conceptCode":"C120309","definition":"A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a gammaretoviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of axicabtagene ciloleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it regulates both the assembly and cell surface expression of TCR complexes. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E1BE14D-4056-4549-E053-F662850A290A","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B294EAA6-9159-4A7B-E053-4EBD850A48B0","beginDate":"2017-11-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-26","modifiedBy":"ONEDATA","dateModified":"2020-10-26","deletedIndicator":"No"},{"value":"Idecabtagene vicleucel","valueDescription":"Idecabtagene Vicleucel","ValueMeaning":{"publicId":"6851615","version":"1","preferredName":"Idecabtagene Vicleucel","longName":"6851615","preferredDefinition":"A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic activities. Upon administration, idecabtagene vicleucel specifically recognizes and kills BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idecabtagene Vicleucel","conceptCode":"C117729","definition":"A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic activities. Upon administration, idecabtagene vicleucel specifically recognizes and kills BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9010C3C7-1819-0D51-E053-F662850AE3E0","latestVersionIndicator":"Yes","beginDate":"2019-08-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-08-14","modifiedBy":"ONEDATA","dateModified":"2019-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B294EAA6-9163-4A7B-E053-4EBD850A48B0","beginDate":"2019-08-14","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-26","modifiedBy":"ONEDATA","dateModified":"2020-10-26","deletedIndicator":"No"},{"value":"Letetresgene autoleucel","valueDescription":"Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794","ValueMeaning":{"publicId":"7479347","version":"1","preferredName":"Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794","longName":"7479347","preferredDefinition":"Human autologous T-lymphocytes transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 (LAGE-1; Cancer/Testis Antigen 2; CTAG2; CT2), with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, the autologous anti-NY-ESO1/LAGE-1 TCR-transduced c259 T-lymphocytes GSK3377794 specifically target and bind to NY-ESO-1/LAGE-1-overexpressing tumor cells. This may result in a cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1/LAGE-1-positive cancer cells. NY-ESO-1 and LAGE-1, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Letetresgene Autoleucel","conceptCode":"C121379","definition":"Human autologous T-lymphocytes transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 (LAGE-1; Cancer/Testis Antigen 2; CTAG2; CT2), with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, letetresgene autoleucel specifically target and bind to NY-ESO-1/LAGE-1-overexpressing tumor cells. This may result in a cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1/LAGE-1-positive cancer cells. NY-ESO-1 and LAGE-1, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B294EAA6-91E8-4A7B-E053-4EBD850A48B0","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-26","modifiedBy":"ONEDATA","dateModified":"2020-10-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B294EAA6-9201-4A7B-E053-4EBD850A48B0","beginDate":"2020-10-22","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-26","modifiedBy":"ONEDATA","dateModified":"2020-10-26","deletedIndicator":"No"},{"value":"Orvacabtagene autoleucel","valueDescription":"Orvacabtagene Autoleucel","ValueMeaning":{"publicId":"7476584","version":"1","preferredName":"Orvacabtagene Autoleucel","longName":"7476584","preferredDefinition":"A preparation of autologous CD4- and CD8-positive T-lymphocytes that have been ex vivo transduced with a genetically-engineered lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137) and the CD3-zeta (CD3z) T-cell signaling domain, with potential immunostimulating and antineoplastic activities. Upon administration, orvacabtagene autoleucel specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Orvacabtagene Autoleucel","conceptCode":"C147523","definition":"A preparation of autologous CD4- and CD8-positive T-lymphocytes that have been ex vivo transduced with a genetically-engineered lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137) and the CD3-zeta (CD3z) T-cell signaling domain, with potential immunostimulating and antineoplastic activities. Upon administration, orvacabtagene autoleucel specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B245F48B-CC3C-2DD4-E053-4EBD850A721F","latestVersionIndicator":"Yes","beginDate":"2020-10-22","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-22","modifiedBy":"ONEDATA","dateModified":"2020-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B294EAA6-9177-4A7B-E053-4EBD850A48B0","beginDate":"2020-10-22","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-26","modifiedBy":"ONEDATA","dateModified":"2020-10-26","deletedIndicator":"No"},{"value":"Ciltacabtagene autoleucel","valueDescription":"Ciltacabtagene Autoleucel","ValueMeaning":{"publicId":"7476588","version":"1","preferredName":"Ciltacabtagene Autoleucel","longName":"7476588","preferredDefinition":"A preparation of autologous T-lymphocytes that are transduced, ex vivo, with LCAR-B38M, a lentiviral vector expressing a chimeric antigen receptor (CAR) containing two bispecific anti-B-cell maturation antigen (BCMA) variable fragments of llama heavy-chain murine antibodies fused to the signaling domain of 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. The antigen-binding region of the CAR is a non-scFv structure targeting two distinct regions of BCMA. Upon intravenous administration back into the patient, ciltacabtagene autoleucel are directed to cells expressing BCMA, bind to two different epitopes on BCMA and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-associated antigen (TAA) and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is overexpressed on malignant plasma cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ciltacabtagene Autoleucel","conceptCode":"C148498","definition":"A preparation of autologous T-lymphocytes that are transduced, ex vivo, with LCAR-B38M, a lentiviral vector expressing a chimeric antigen receptor (CAR) containing two bispecific anti-B-cell maturation antigen (BCMA) variable fragments of llama heavy-chain murine antibodies fused to the signaling domain of 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. The antigen-binding region of the CAR is a non-scFv structure targeting two distinct regions of BCMA. Upon intravenous administration back into the patient, ciltacabtagene autoleucel are directed to cells expressing BCMA, bind to two different epitopes on BCMA and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-associated antigen (TAA) and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is overexpressed on malignant plasma cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B245F48B-CC88-2DD4-E053-4EBD850A721F","latestVersionIndicator":"Yes","beginDate":"2020-10-22","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-22","modifiedBy":"ONEDATA","dateModified":"2020-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B294EAA6-918B-4A7B-E053-4EBD850A48B0","beginDate":"2020-10-22","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-26","modifiedBy":"ONEDATA","dateModified":"2020-10-26","deletedIndicator":"No"},{"value":"Brexucabtagene autoleucel","valueDescription":"Brexucabtagene Autoleucel","ValueMeaning":{"publicId":"7476590","version":"1","preferredName":"Brexucabtagene Autoleucel","longName":"7476590","preferredDefinition":"A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of abrexucabtagene autoleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it regulates both the assembly and cell surface expression of TCR complexes. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development. KTE-X19 has the same construct as axicabtagene ciloleucel, but differs in the manufacturing process in that KTE-X19 includes specific T-cell selection and lymphocyte enrichment necessary for activity against certain B-cell malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brexucabtagene Autoleucel","conceptCode":"C170439","definition":"A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of abrexucabtagene autoleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it regulates both the assembly and cell surface expression of TCR complexes. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development. KTE-X19 has the same construct as axicabtagene ciloleucel, but differs in the manufacturing process in that KTE-X19 includes specific T-cell selection and lymphocyte enrichment necessary for activity against certain B-cell malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B245F48B-CCAE-2DD4-E053-4EBD850A721F","latestVersionIndicator":"Yes","beginDate":"2020-10-22","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-22","modifiedBy":"ONEDATA","dateModified":"2020-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B294EAA6-9195-4A7B-E053-4EBD850A48B0","beginDate":"2020-10-22","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-26","modifiedBy":"ONEDATA","dateModified":"2020-10-26","deletedIndicator":"No"},{"value":"No product name","valueDescription":"Negation Product Name","ValueMeaning":{"publicId":"7479345","version":"1","preferredName":"Negation Product Name","longName":"7479345","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: The end result of a manufacturing process; anything that is produced.: The words or language units by which a thing is known.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Product","conceptCode":"C51980","definition":"The end result of a manufacturing process; anything that is produced.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B294EAA6-91C2-4A7B-E053-4EBD850A48B0","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-26","modifiedBy":"KUMMEROA","dateModified":"2020-10-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B294EAA6-91DB-4A7B-E053-4EBD850A48B0","beginDate":"2020-10-26","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-26","modifiedBy":"ONEDATA","dateModified":"2020-10-26","deletedIndicator":"No"},{"value":"Afamitresgene autoleucel","valueDescription":null,"ValueMeaning":{"publicId":"13300999","version":"1","preferredName":"Afamitresgene Autoleucel","longName":"13300999v1.00","preferredDefinition":"A preparation of autologous human T-lymphocytes transduced with a lentiviral vector encoding an affinity-enhanced T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A2-restricted peptide human melanoma antigen A4 (MAGE-A4) C1032, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, afamitresgene autoleucel targets and binds to tumor cells expressing MAGE-A4. This results in cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen (TAA) MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Afamitresgene Autoleucel","conceptCode":"C175738","definition":"A preparation of autologous human T-lymphocytes transduced with a lentiviral vector encoding an affinity-enhanced T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A2-restricted peptide human melanoma antigen A4 (MAGE-A4) C1032, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, afamitresgene autoleucel targets and binds to tumor cells expressing MAGE-A4. This results in cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen (TAA) MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F876E54C-8B26-1D65-E053-731AD00AC0CD","latestVersionIndicator":"Yes","beginDate":"2023-04-03","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-03","modifiedBy":"GDEEN","dateModified":"2023-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F876E54C-8B27-1D65-E053-731AD00AC0CD","beginDate":"2023-04-03","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-03","modifiedBy":"GDEEN","dateModified":"2023-04-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435032","version":"1","preferredName":"Property or Attribute","preferredDefinition":"The distinguishing qualities or prominent aspect of a person, object, action, process, or substance.","longName":"C20189","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-8321-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6028569","version":"1","preferredName":"Manufacture Cellular Therapy Product Type","preferredDefinition":"The act of making something (a product) from raw materials.:Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.:The end result of a manufacturing process; anything that is produced.:Something distinguishable as an identifiable class based on common qualities.","longName":"C43360:C70601:C51980:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Manufacture","conceptCode":"C43360","definition":"The act of making something (a product) from raw materials.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cellular Therapy","conceptCode":"C70601","definition":"Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Product","conceptCode":"C51980","definition":"The end result of a manufacturing process; anything that is produced.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E1BE14D-4006-4549-E053-F662850A290A","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B294EAA6-9125-4A7B-E053-4EBD850A48B0","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-26","modifiedBy":"GDEEN","dateModified":"2023-04-03","changeDescription":"Released. 01/28/2021 KMM; . Added new PVs. AK 8/14/19. Added PVs for the 4006r5. 10/22/2020 KMM. Versioned VD. 10/26/2020 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"CTI_PI_manuf_ct_prd_ty","type":"NMDP_FN","context":"NHLBI"},{"name":"CTP_CTPI_manuf_ct_prd_ty","type":"NMDP_FN","context":"NHLBI"},{"name":"CPRE_DIM_manuf_ct_prd_ty","type":"NMDP_FN","context":"NHLBI"},{"name":"CPRE_PI_manuf_ct_prd_ty","type":"NMDP_FN","context":"NHLBI"},{"name":"CPST_PRD_manuf_ct_prd_ty","type":"NMDP_FN","context":"NHLBI"},{"name":"CFUP_PRD_manuf_ct_prd_ty","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the manufactured cel","type":"Preferred Question Text","description":"What was the manufactured cellular therapy product?","url":null,"context":"NHLBI"},{"name":"Name of product","type":"Alternate Question Text","description":"Name of product","url":null,"context":"NHLBI"},{"name":"Name of product","type":"Application Standard Question Text","description":"Name of product","url":null,"context":"NHLBI"},{"name":"Name of cellular therapy product","type":"Alternate Question Text","description":"Name of cellular therapy product","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B295582A-7383-5BD1-E053-4EBD850AEF07","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-26","modifiedBy":"KUMMEROA","dateModified":"2023-05-08","changeDescription":"Released. 01/28/2021 KMM; . System generated def displayed as alt def. Added Field name for 4100r4r. AK 10/10/18. Added AQT. 10/22/2020 KMM. Version CDE due to newer version VD. 10/26/2020 KMM. ALT name added for 4100r6. 06/03/2021 KMM","administrativeNotes":"2023.5.8 Alt name added per ticket request CADSR0002399. ak","unresolvedIssues":null,"deletedIndicator":"No"}}